Cargando…
Pharmacokinetic Properties of DNA Aptamers with Base Modifications
The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of app...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706628/ https://www.ncbi.nlm.nih.gov/pubmed/28961063 http://dx.doi.org/10.1089/nat.2017.0683 |
_version_ | 1783282259896303616 |
---|---|
author | Gupta, Shashi Drolet, Daniel W. Wolk, Steven K. Waugh, Sheela M. Rohloff, John C. Carter, Jeffery D. Mayfield, Wesley S. Otis, Matthew R. Fowler, Catherine R. Suzuki, Tomoki Hirota, Masao Ishikawa, Yuichi Schneider, Daniel J. Janjic, Nebojsa |
author_facet | Gupta, Shashi Drolet, Daniel W. Wolk, Steven K. Waugh, Sheela M. Rohloff, John C. Carter, Jeffery D. Mayfield, Wesley S. Otis, Matthew R. Fowler, Catherine R. Suzuki, Tomoki Hirota, Masao Ishikawa, Yuichi Schneider, Daniel J. Janjic, Nebojsa |
author_sort | Gupta, Shashi |
collection | PubMed |
description | The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of applications, especially for therapeutics. In this study, we assess the impact of these side chains on plasma pharmacokinetics of modified aptamers conjugated to a 40 kDa polyethylene glycol. We show that clearance from plasma depends on relative hydrophobicity: side chains with a negative cLogP (more hydrophilic) result in slower plasma clearance compared with side chains with a positive cLogP (more hydrophobic). We show that clearance increases with the number of side chains in sequences of ≥28 synthons, but this effect is dramatically diminished in shorter sequences. These results serve as a guide for the design of new therapeutic aptamers with diversity-enhancing side chains. |
format | Online Article Text |
id | pubmed-5706628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57066282017-12-01 Pharmacokinetic Properties of DNA Aptamers with Base Modifications Gupta, Shashi Drolet, Daniel W. Wolk, Steven K. Waugh, Sheela M. Rohloff, John C. Carter, Jeffery D. Mayfield, Wesley S. Otis, Matthew R. Fowler, Catherine R. Suzuki, Tomoki Hirota, Masao Ishikawa, Yuichi Schneider, Daniel J. Janjic, Nebojsa Nucleic Acid Ther Original Articles The addition of novel side chains at the 5-position of uracil is an effective means to increase chemical diversity of aptamers and hence the success rate for discovery of high-affinity ligands to protein targets. Such modifications also increase nuclease resistance, which is useful in a range of applications, especially for therapeutics. In this study, we assess the impact of these side chains on plasma pharmacokinetics of modified aptamers conjugated to a 40 kDa polyethylene glycol. We show that clearance from plasma depends on relative hydrophobicity: side chains with a negative cLogP (more hydrophilic) result in slower plasma clearance compared with side chains with a positive cLogP (more hydrophobic). We show that clearance increases with the number of side chains in sequences of ≥28 synthons, but this effect is dramatically diminished in shorter sequences. These results serve as a guide for the design of new therapeutic aptamers with diversity-enhancing side chains. Mary Ann Liebert, Inc. 2017-12-01 2017-12-01 /pmc/articles/PMC5706628/ /pubmed/28961063 http://dx.doi.org/10.1089/nat.2017.0683 Text en © Shashi Gupta et al. 2017; Published by Mary Ann Liebert, Inc. This article is available under the Creative Commons License CC-BY-NC (http://creativecommons.org/licenses/by-nc/4.0). This license permits non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. Permission only needs to be obtained for commercial use and can be done via RightsLink. |
spellingShingle | Original Articles Gupta, Shashi Drolet, Daniel W. Wolk, Steven K. Waugh, Sheela M. Rohloff, John C. Carter, Jeffery D. Mayfield, Wesley S. Otis, Matthew R. Fowler, Catherine R. Suzuki, Tomoki Hirota, Masao Ishikawa, Yuichi Schneider, Daniel J. Janjic, Nebojsa Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
title | Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
title_full | Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
title_fullStr | Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
title_full_unstemmed | Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
title_short | Pharmacokinetic Properties of DNA Aptamers with Base Modifications |
title_sort | pharmacokinetic properties of dna aptamers with base modifications |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706628/ https://www.ncbi.nlm.nih.gov/pubmed/28961063 http://dx.doi.org/10.1089/nat.2017.0683 |
work_keys_str_mv | AT guptashashi pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT droletdanielw pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT wolkstevenk pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT waughsheelam pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT rohloffjohnc pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT carterjefferyd pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT mayfieldwesleys pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT otismatthewr pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT fowlercatheriner pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT suzukitomoki pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT hirotamasao pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT ishikawayuichi pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT schneiderdanielj pharmacokineticpropertiesofdnaaptamerswithbasemodifications AT janjicnebojsa pharmacokineticpropertiesofdnaaptamerswithbasemodifications |